Advertisement
Screener

MARKER THERAPEUTICS, INC. (MRKR) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

MARKER THERAPEUTICS, INC. Operating Expenses

MARKER THERAPEUTICS, INC. (MRKR) reported Operating Expenses of $2.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2026-08-14

  • MARKER THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $2.62M, a 48.84% decline year-over-year.
  • MARKER THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $4.07M, a 17.86% decline year-over-year.
  • MARKER THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $2.99M, a 51.13% decline year-over-year.
  • MARKER THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $3.37M, a 22.10% decline year-over-year.
  • MARKER THERAPEUTICS, INC. operating expenses for fiscal 2025 was $16.44M, a 7.18% decline from fiscal 2024.
  • MARKER THERAPEUTICS, INC. operating expenses for fiscal 2024 was $17.71M, a 1.02% decline from fiscal 2023.
  • MARKER THERAPEUTICS, INC. operating expenses for fiscal 2023 was $17.89M, a 23.22% decline from fiscal 2022.
  • MARKER THERAPEUTICS, INC. operating expenses for fiscal 2022 was $23.30M, a 42.77% decline from fiscal 2021.
Period endOperating Expenses 3 monthOperating Expenses 3 month as first filedOperating Expenses 6 monthOperating Expenses 6 month as first filedOperating Expenses 9 monthOperating Expenses 9 month as first filedOperating Expenses 12 monthOperating Expenses 12 month as first filed
2026-06-30$2.62M
10-Q · filed 2026-08-14
$6.69M
10-Q · filed 2026-08-14
$9.68M
derived: sum of 3 quarters · filed 2026-08-14
$13.05M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$4.07M
10-Q · filed 2026-05-15
$7.06M
derived: sum of 2 quarters · filed 2026-05-15
$10.43M
derived: sum of 3 quarters · filed 2026-05-15
$15.55M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$2.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$6.36M
derived: sum of 2 quarters · filed 2026-03-18
$11.48M
derived: sum of 3 quarters · filed 2026-08-14
$16.44M
10-K · filed 2026-03-18
2025-09-30$3.37M
10-Q · filed 2025-11-13
$8.49M
derived: sum of 2 quarters · filed 2026-08-14
$13.45M
10-Q · filed 2025-11-13
$19.56M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30$5.12M
10-Q · filed 2026-08-14
$10.08M
10-Q · filed 2026-08-14
$16.19M
derived: sum of 3 quarters · filed 2026-08-14
$20.52M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$4.96M
10-Q · filed 2026-05-15
$11.07M
derived: sum of 2 quarters · filed 2026-05-15
$15.40M
derived: sum of 3 quarters · filed 2026-05-15
$18.87M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31$6.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$10.44M
derived: sum of 2 quarters · filed 2026-03-18
$13.92M
derived: sum of 3 quarters · filed 2026-03-18
$17.71M
10-K · filed 2026-03-18
2024-09-30$4.33M
10-Q · filed 2025-11-13
$7.80M
derived: sum of 2 quarters · filed 2025-11-13
$11.60M
10-Q · filed 2025-11-13
$15.59M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$3.48M
10-Q · filed 2025-08-14
$7.27M
10-Q · filed 2025-08-14
$11.26M
derived: sum of 3 quarters · filed 2025-08-14
$14.72M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$3.79M
10-Q · filed 2025-05-15
$7.79M
derived: sum of 2 quarters · filed 2025-05-15
$11.25M
derived: sum of 3 quarters · filed 2025-05-15
$16.14M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31$3.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$7.45M
derived: sum of 2 quarters · filed 2025-03-31
$12.35M
derived: sum of 3 quarters · filed 2025-03-31
$17.89M
10-K · filed 2025-03-31
2023-09-30$3.46M
10-Q · filed 2024-11-14
$8.35M
derived: sum of 2 quarters · filed 2024-11-14
$13.90M
10-Q · filed 2024-11-14
$17.70M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$4.90M
10-Q · filed 2024-08-14
$10.44M
10-Q · filed 2024-08-14
$14.24M
derived: sum of 3 quarters · filed 2024-08-14
$21.06M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31$5.54M
10-Q · filed 2024-05-15
$9.79M
10-Q · filed 2023-05-15
$9.34M
derived: sum of 2 quarters · filed 2024-05-15
$16.17M
derived: sum of 3 quarters · filed 2024-05-15
$22.23M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31$3.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26
$10.62M
derived: sum of 2 quarters · filed 2024-03-26
$16.68M
derived: sum of 3 quarters · filed 2024-03-26
$23.30M
10-K · filed 2024-03-26
$38.96M
10-K · filed 2023-03-22
2022-09-30$6.83M
10-Q · filed 2023-11-09
$10.97M
10-Q · filed 2022-11-10
$12.89M
derived: sum of 2 quarters · filed 2023-11-09
$19.51M
10-Q · filed 2023-11-09
$31.80M
10-Q · filed 2022-11-10
$34.65M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30$6.06M
10-Q · filed 2023-08-14
$10.07M
10-Q · filed 2022-08-11
$12.68M
10-Q · filed 2023-08-14
$20.83M
10-Q · filed 2022-08-11
$27.82M
derived: sum of 3 quarters · filed 2023-08-14
$37.85M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31$10.76M
10-Q · filed 2023-05-15
$21.77M
derived: sum of 2 quarters · filed 2023-05-15
$31.79M
derived: sum of 3 quarters · filed 2023-05-15
$42.70M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31$11.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22
$21.03M
derived: sum of 2 quarters · filed 2023-03-22
$31.94M
derived: sum of 3 quarters · filed 2023-03-22
$40.72M
10-K · filed 2023-03-22
2021-09-30$10.02M
10-Q · filed 2022-11-10
$20.93M
derived: sum of 2 quarters · filed 2022-11-10
$29.71M
10-Q · filed 2022-11-10
$38.22M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30$10.91M
10-Q · filed 2022-08-11
$19.69M
10-Q · filed 2022-08-11
$28.20M
derived: sum of 3 quarters · filed 2022-08-11
$35.57M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31$8.78M
10-Q · filed 2022-05-13
$17.29M
derived: sum of 2 quarters · filed 2022-05-13
$24.67M
derived: sum of 3 quarters · filed 2022-05-13
$31.49M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31$8.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
$15.88M
derived: sum of 2 quarters · filed 2022-03-17
$22.71M
derived: sum of 3 quarters · filed 2022-03-17
$29.35M
10-K · filed 2022-03-17
2020-09-30$7.38M
10-Q · filed 2021-11-10
$14.20M
derived: sum of 2 quarters · filed 2021-11-10
$20.84M
10-Q · filed 2021-11-10
$26.42M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$6.82M
10-Q · filed 2021-08-10
$13.47M
10-Q · filed 2021-08-10
$19.04M
derived: sum of 3 quarters · filed 2021-08-10
$24.70M
derived: sum of 4 quarters · filed 2021-08-10
2020-03-31$6.64M
10-Q · filed 2021-05-12
$12.22M
derived: sum of 2 quarters · filed 2021-05-12
$17.87M
derived: sum of 3 quarters · filed 2021-05-12
$23.75M
derived: sum of 4 quarters · filed 2021-05-12
2019-12-31$5.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09
$11.23M
derived: sum of 2 quarters · filed 2021-03-09
$17.10M
derived: sum of 3 quarters · filed 2021-03-09
$22.74M
10-K · filed 2021-03-09
2019-09-30$5.65M
10-Q · filed 2020-11-09
$11.53M
derived: sum of 2 quarters · filed 2020-11-09
$17.17M
10-Q · filed 2020-11-09
$153.04M
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30$5.87M
10-Q · filed 2020-08-10
$11.51M
10-Q · filed 2020-08-10
$147.38M
derived: sum of 3 quarters · filed 2020-08-10
$151.81M
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31$5.64M
10-Q · filed 2020-05-11
$141.51M
derived: sum of 2 quarters · filed 2020-05-11
$145.94M
derived: sum of 3 quarters · filed 2020-05-11
$150.82M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31$135.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$140.30M
derived: sum of 2 quarters · filed 2020-03-12
$145.18M
derived: sum of 3 quarters · filed 2020-03-12
$148.38M
10-K · filed 2020-03-12
2018-09-30$4.43M
10-Q · filed 2019-11-12
$9.31M
derived: sum of 2 quarters · filed 2019-11-12
$12.51M
10-Q · filed 2019-11-12
$15.19M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$4.88M
10-Q · filed 2019-08-09
$8.08M
10-Q · filed 2019-08-09
$10.76M
derived: sum of 3 quarters · filed 2019-08-09
$14.93M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31$3.20M
10-Q · filed 2019-05-10
$5.88M
derived: sum of 2 quarters · filed 2019-05-10
$10.05M
derived: sum of 3 quarters · filed 2019-05-10
$12.44M
derived: sum of 4 quarters · filed 2019-05-10
2017-12-31$2.68M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15
$6.85M
derived: sum of 2 quarters · filed 2019-03-15
$9.25M
derived: sum of 3 quarters · filed 2019-03-15
$11.66M
10-K · filed 2019-03-15
2017-09-30$4.17M
10-Q · filed 2018-11-13
$6.57M
derived: sum of 2 quarters · filed 2018-11-13
$8.98M
10-Q · filed 2018-11-13
$10.57M
derived: sum of 4 quarters · filed 2018-11-13
2017-06-30$2.39M
10-Q · filed 2018-08-09
$4.81M
10-Q · filed 2018-08-09
$6.40M
derived: sum of 3 quarters · filed 2018-08-09
$9.12M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31$2.42M
10-Q · filed 2018-05-15
$4.01M
derived: sum of 2 quarters · filed 2018-05-15
$6.73M
derived: sum of 3 quarters · filed 2018-05-15
$9.16M
derived: sum of 4 quarters · filed 2018-05-15
2016-12-31$1.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-23
$4.31M
derived: sum of 2 quarters · filed 2018-03-23
$6.74M
derived: sum of 3 quarters · filed 2018-03-23
$8.49M
10-K · filed 2018-03-23
2016-09-30$2.72M
10-Q · filed 2017-11-14
$5.15M
derived: sum of 2 quarters · filed 2017-11-14
$6.90M
10-Q · filed 2017-11-14
2016-06-30$2.43M
10-Q · filed 2017-08-07
$4.18M
10-Q · filed 2017-08-07
2016-03-31$1.75M
10-Q · filed 2017-05-05
2015-09-30$1.74M
10-Q/A · filed 2016-04-14
$3.90M
10-Q/A · filed 2016-04-14
2014-09-30$1.38M
10-Q/A · filed 2016-04-14
$2.98M
10-Q/A · filed 2016-04-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Rocket One Inc. (RKTO)United States$0.019B
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Lipocine Inc. (LPCN)United States$0.017B-1.79
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66